Exploring miRNAs’ Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis

Author:

Gosetti di Sturmeck Tommaso1,Malimpensa Leonardo2ORCID,Ferrazzano Gina3,Belvisi Daniele23,Leodori Giorgio23ORCID,Lembo Flaminia3,Brandi Rossella1,Pascale Esterina4ORCID,Cattaneo Antonino15,Salvetti Marco26ORCID,Conte Antonella23ORCID,D’Onofrio Mara1,Arisi Ivan17

Affiliation:

1. European Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy

2. IRCCS Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy

3. Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy

4. Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy

5. Bio@SNS Laboratory of Biology, Scuola Normale Superiore (SNS), 56126 Pisa, Italy

6. Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, 00189 Rome, Italy

7. Institute of Translational Pharmacology, National Research Council, 00133 Rome, Italy

Abstract

The current hypothesis on the pathophysiology of multiple sclerosis (MS) suggests the involvement of both inflammatory and neurodegenerative mechanisms. Disease Modifying Therapies (DMTs) effectively decrease relapse rates, thus reducing relapse-associated disability in people with MS. In some patients, disability progression, however, is not solely linked to new lesions and clinical relapses but can manifest independently. Progression Independent of Relapse Activity (PIRA) significantly contributes to long-term disability, stressing the urge to unveil biomarkers to forecast disease progression. Twenty-five adult patients with relapsing–remitting multiple sclerosis (RRMS) were enrolled in a cohort study, according to the latest McDonald criteria, and tested before and after high-efficacy Disease Modifying Therapies (DMTs) (6–24 months). Through Agilent microarrays, we analyzed miRNA profiles from peripheral blood mononuclear cells. Multivariate logistic and linear models with interactions were generated. Robustness was assessed by randomization tests in R. A subset of miRNAs, correlated with PIRA, and the Expanded Disability Status Scale (EDSS), was selected. To refine the patient stratification connected to the disease trajectory, we computed a robust logistic classification model derived from baseline miRNA expression to predict PIRA status (AUC = 0.971). We built an optimal multilinear model by selecting four other miRNA predictors to describe EDSS changes compared to baseline. Multivariate modeling offers a promising avenue to uncover potential biomarkers essential for accurate prediction of disability progression in early MS stages. These models can provide valuable insights into developing personalized and effective treatment strategies.

Funder

Regione Lazio

Ministry of University and Research (MUR

Fondo Ordinario Enti

Publisher

MDPI AG

Reference54 articles.

1. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy;Ghasemi;Cell J.,2017

2. Multiple Sclerosis;Jakimovski;Lancet,2024

3. The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs;Bebo;Neurology,2022

4. Toward Precision Phenotyping of Multiple Sclerosis;Pitt;Neurol. Neuroimmunol. Neuroinflamm.,2022

5. Evolving Concepts in the Treatment of Relapsing Multiple Sclerosis;Comi;Lancet,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3